Law360, New York (June 13, 2008, 12:00 AM ET) -- Three Johnson & Johnson subsidiaries launched a patent infringement suit last week against Novartis AG’s generics arm, Sandoz Inc., after the generics maker filed an abbreviated new drug application for the Alzheimer’s drug Razadyne ER.
The complaint filed in the U.S. District Court for the District of New Jersey alleges Sandoz’s ANDA filing with the U.S. Food and Drug Administration infringes on a patent held by Janssen LLP, a Johnson & Johnson unit.
Sandoz allegedly intends to bring to market a generic version of galantamine hydrobromide...
Janssen Sues Sandoz Over Alzheimer's Drug ANDA
To view the full article, take a free trial now.
